A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6,11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults.

Trial Profile

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6,11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Apr 2012 Actual patient number changed from 24 to 26 as reported by ClinicalTrials.gov.
    • 01 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top